Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients

This study has been completed.
Sponsor:
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00139945
First received: August 30, 2005
Last updated: January 19, 2010
Last verified: January 2010

August 30, 2005
January 19, 2010
October 2005
March 2007   (final data collection date for primary outcome measure)
Endogenous serum ghrelin levels [ Time Frame: Same day as intervention ] [ Designated as safety issue: No ]
Endogenous serum ghrelin levels
Complete list of historical versions of study NCT00139945 on ClinicalTrials.gov Archive Site
Insulin sensitivity, appetite, metabolism, intracellular signal transduction [ Time Frame: Same day as intervention ] [ Designated as safety issue: No ]
Insulin sensitivity, appetite, metabolism, intracellular signal transduction
Not Provided
Not Provided
 
Ghrelin, Growth Hormone and Cortisol Interaction in Growth Hormone Deficient Patients
Effects of Acute Ghrelin Infusion to Growth Hormone Deficient Adults: Growth Hormone and Cortisol Interaction

In growth hormone deficient patients: Determination of endogenous circulating ghrelin levels, ghrelin effects on insulin sensitivity, appetite, energy metabolism, and signal transduction in fat and muscle.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Hypopituitarism
Drug: Human acylated ghrelin
5 pmol/kg body weight per min
Not Provided
Vestergaard ET, Gormsen LC, Jessen N, Lund S, Hansen TK, Moller N, Jorgensen JO. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes. 2008 Dec;57(12):3205-10. Epub 2008 Sep 5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
8
March 2007
March 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Age between 18 and 60 yrs.
  • Verified hypopituitarism
  • Unchanged substitution treatment through 3+ months
  • Unchanged additional medical treatment
  • Oral and written informed consent

Exclusion Criteria:

  • Age below 18 or above 60 yrs.
  • Diabetes mellitus
  • body mass index > 30
  • Fasting hypoglycemia
  • Convulsions
  • Allergy to trial products
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
Denmark
 
NCT00139945
2004/102
No
Esben T. Vestergaard/MD PhD, University of Aarhus
University of Aarhus
Not Provided
Principal Investigator: Jens Otto L Jorgensen, DrMedSci Aarhus University Hospital
University of Aarhus
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP